Business
Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome
Results Show Significant Improvements in Hyperphagia and PWS-Related Behaviors in DCCR-Treated Patients Presentations at the Pediatric Academic Societies 2022
About this update from Soleno Therapeutics, Inc.
[{"type":"text","content":"Results Show Significant Improvements in Hyperphagia and PWS-Related Behaviors in DCCR-Treated Patients Presentations at the Pediatric Academic Societies 2022 Virtual Annual Meeting and Pediatric Endocrinology Society 2022 Virtual Annual Meeting REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced two presentations highlighting the results from a study evaluating diazoxide choline extended-release (DCCR) tablets under development for the treatment of Prader-Willi Syndrome (PWS) in patients who completed its DESTINY PWS study and then continued into the open-label extension clinical study (C601/C602). The data were presented by Theresa Strong, Ph.D., Director of Research Programs, Foundation for Prader-Willi Research (FPWR), at the Pediatric Academic Societies 2022 Virtual Annual Meeting, and Jennifer Miller, M.D., Professor in the Division of Pediatric Endocrinology for the University of Florida Department of Pediatrics, at the Pediatric Endocrinology Society 2022 Virtual Annual Meeting. Key highlights from the poster presentation, titled, “Comparison of hyperphagia and behavioral features in Prader-Willi Syndrome (PWS) patients receiving Diazoxide Choline Extended-Release (DCCR) with matched participants in PATH for PWS Study (PfPWS NHS),” presented by Dr. Strong were: Highly statistically significant reductions in HQ-CT total score for C601/C602 compared to the matched PfPWS cohort at Week 26 for propensity-adjusted and non-propensity-adjusted analyses and were sustained at Week 52 (all p","length":2240,"tagName":"div"}]